Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer.

ABSTRACT:

Aims

Cancer therapy-related cardiac dysfunction (CTRCD) is a dreaded complication of anthracycline therapy. CTRCD most frequently appears in patients with cardiovascular risk factors (CVR) or known cardiovascular disease. However, limited data exist on incidence and course of anthracycline-induced CTRCD in patients without preexisting risk factors. We therefore aimed to longitudinally investigate a cohort of young women on anthracycline treatment due to breast cancer without cardiovascular risk factors or known cardiovascular disease (NCT03940625).

Methods and results

We enrolled 59 women with primary breast cancer and scheduled anthracycline-based therapy, but without CVR or preexisting cardiovascular disease. We conducted a longitudinal assessment before, immediately and 1

SUBMITTER: Voß F 

PROVIDER: S-EPMC11251313 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature